艾伯维Abbvie Inc (ABBV) 2013年年度报告「NYSE」.pdf

1、AbbVie1 North Waukegan Road North Chicago,IL 60064 U.S.ACopyright 2014 AbbVie.All rights reserved.2013 annual report on form 10-k2014 notice of annual meeting AND proxy statement9893_AbbVie.indd 12/4/14 8:38 PMabout abbvieAbbVie is a global,research-based biopharmaceutical company formed in 2013 fol

2、lowing separation from Abbott Laboratories.The companys mission is to use its expertise,dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the worlds most complex and serious diseases.AbbVie employs approximately 25,000 people worldwide a

3、nd markets medicines in more than 170 countries.For further information on the company and its people,portfolio and commitments,please visit .9893_AbbVie.indd 22/4/14 8:38 PM13NOV2012213657664DEC201212233206Dear AbbVie Stockholder:We had a highly successful inaugural year as an independent company,a

4、nd wedelivered strong results.Our goals for 2013 included delivering top-tier financialperformance,maximizing our on-market product portfolio and advancing ourlate-stage pipeline,including our novel HCV therapy.We met or exceeded all of thesecommitments,while at the same time expanded our pipeline t

5、hrough both internalR&D efforts and external collaborations that position the company for continuedfuture success.We delivered strong financial performance in 2013,with a total stockholder returnin excess of 60 percent.Total revenue grew to$18.8 billion,driven by our flagshipmedicine Humirawhich inc

6、reased in worldwide sales by 15 percentand the stronggrowth of our other on-market products.We made significant progress in advancing several of our late-stage compoundsinto Phase III studies and completed the Hepatitis C clinical program,keeping us ontrack to submit for regulatory approval in the s